News

Devdiscourse5d
WHO Endorses Lenacapavir for Twice-Yearly HIV Prevention in Landmark Update
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...
The Nation Newspaper5d
WHO backs new injectable HIV prevention drug
The World Health Organisation (WHO) has for the first time recommended the use of injectable lenacapavir (LEN) as a ...
WHO announces lenacapavir as a groundbreaking HIV prevention method
Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...
WHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the ...